NEW: No-Cost Streetwise Live! Events. This type of intellectual capital is usually not made available to the general public. Learn More
VIV:TSX.V; VIVXF:OTCQB

Avivagen Inc.

Avivagen is developing and commercializing products that promote health in animals and humans. The Corporation’s unique OxC-beta™ technology is a proprietary, first-in-class source of β-carotene-oxygen copolymer compounds that confer a variety of non-vitamin A health benefits. These benefits have wide, global utility, including replacement of antibiotics in livestock feeds, as well as for food-production conditions where antibiotics cannot be used, and supporting good health in companion animals.
VIV:TSX.V VIVXF:OTCQB
View Company News
Visit Company Website

Expert Comments:

SmallCapsDaily

(7/23/20)
"Enhancing livestock health without the use of antibiotics has become a must in order to prevent the emergence of deadly diseases including so called superbugs. Avivagen Inc. is a Life Sciences player that caters directly to this need and is at a very interesting juncture today. The company is building a compelling growth story as it has gone on to receive numerous country approvals across many large livestock markets in the world."

Life Sciences Firm Gains Approval to Sell Non-Antibiotic Livestock Feed Additive in Brazil
(6/25/20)

Avivagen reported it received approval for use of OxC-beta™ Livestock in Brazil and it has signed an agreement with a São Paulo company for distribution.
read more >

David Bautz, Zacks Small-Cap Research

(6/9/20)
"Avivagen Inc. recently announced an upsized order of OxC-beta Livestock from Mexico-based Industrias Melder following positive results from two dairy animal tests conducted by one of Industrias Melder's key customers. This initial sale could lead to a formal long-term relationship and help Avivagen enter the Mexican market, which has annual feed sales of 36 Mt." —Zacks Small-Cap Research

Positive Test Results in Dairy Cows Lead to Upsized Livestock Supplement Order
(5/21/20)

With this sale, Avivagen's antibiotics-free, immune-boosting feed additive enters the Mexican market.
read more >

Company Secures Largest Order to Date for Antibiotic-Free Feedstock Supplement
(4/8/20)

Avivagen Inc. has secured its largest ever order of OxC-beta™ Livestock from its long-standing Philippine partner UNAHCO.
read more >

Animal Feed Supplement Maker Expands Asia Footprint
(4/4/20)

Avivagen receives new orders from two eastern countries for its product.
read more >

Maker of Antibiotic-Free Animal Supplement Lands First Order from Mexico
(3/26/20)

This new market is a significant one for Avivagen.
read more >

Firm to Accelerate Launch of Immune Booster for Humans
(3/18/20)

Avivagen hires a firm to assist with the product's commercial debut.
read more >

David Bautz, Zacks Small-Cap Research

(3/11/20)
"Avivagen Inc. announced positive and statistically significant results from its New Zealand dairy trial showing that OxC-beta has an effect against subclinical mastitis. There was a 13.9% rate of resolution of bacterial infection in cows fed feed containing OxC-beta compared to a 6.9% resolution rate in the group fed the control feed containing no antibiotics." — -Zacks Small-Cap Research

Avivagen to Be Featured on BioPub Webcast Hosted by Dr. KSS MD PhD on March 6
(3/5/20)

Webcast will be at 12 noon ET on Friday, March 6.
read more >

Life Sciences Firm Contracts with Philippines Distributor
(2/18/20)

This agreement will provide another sales channel and additional revenue opportunities for Avivagen's proprietary product.
read more >

Clive Maund, CliveMaund.com

(1/31/20)
"Given the huge strides that Avivagen Inc. is making towards its objectives, it is truly astounding that its stock hasn't taken off higher already, especially given that it still has a relatively modest number of shares in issue. . .it looks like it could very soon. . .the company looks like a most attractive stock here, so we stay long and it is rated an immediate Strong Buy."

David Bautz, Zacks Small-Cap Research

(1/10/20)
"Avivagen Inc. entered into an agreement with COFCO Biotechnology Co. Ltd. in which COFCO will assist the company in securing regulatory approval for OxC-beta Livestock in China. . .we believe it is a great partner to assist Avivagen. . .China represents a tremendous opportunity for it as the Chinese government has announced a plan to ban all antibiotics in livestock feed by July 2020." — -Zacks Small-Cap Research

David Bautz, Zacks Small-Cap Research

(11/19/19)
"We are initiating coverage of Avivagen Inc. with a $2.50 valuation. The company is developing products to support animal health, which includes replacing antibiotics in livestock feeds with proprietary compounds that promote the growth and overall health of the animal through support of the host's innate immune system." -Zacks Small-Cap Research

More Expert Comments

Experts Following This Company

Clive Maund – CliveMaund.com

The information provided above is from analysts, newsletters, the company and other contributors.

Avivagen Inc. is a sponsor of Streetwise Reports. The company's sponsorship fees pay for Streetwise Reports to create and update this "Investor Summary Page," to which links are placed on Streetwise Reports' websites and newsletters. Streetwise Reports does not accept stock for the payment of fees. See disclaimer for more details.

The company description, investing highlights and catalyst calendar on this page were prepared by the company. The Expert Comments and Experts Following This Company sections of this page are compiled by Streetwise Reports. There may be other information about the company that is not placed on this page. Streetwise Reports does not guarantee the accuracy or thoroughness of the information contained on this page.

The Expert Opinions above are excerpted from third-party sources not affiliated with or controlled by Streetwise Reports. The statements or opinions expressed in the Expert Opinions above are those of the authors indicated, and Streetwise Reports has not verified the accuracy of material excerpted here. Publications excerpted above may receive payment or sponsorship from the company mentioned.

Streetwise Reports does not provide investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security.Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.

Readers should conduct their own research for all information publicly available concerning the company.

Investing Highlights
 
 Effective natural substitute for antibiotics in animal feed
 
 Six families of patents extending beyond 2035
 
 Antibiotic ban in animal feed being led by Governments
catalyst Calendar
Q1
2019
Nutraceutical deal/JV
Q3
2019
GRAS approval for livestock in the USA
Q4
2019
Chinese approval for livestock
Avivagen Inc. Content
go
Company Presentation September 2018

 play
Testing shrimp for antibiotic-resistant bacteria (Marketplace) Premiered Mar 15, 2019 CBC News